Our #BOPA#EDI publication is now available!
Equity, diversity & inclusion in oncology pharmacy practice: Everyone's business
https://t.co/clOFfzAcJW
@Jurgmondo@DolapomSanni@oncology_pharm
@StevePharmacist @shereenabhani
It is so heartwarming to see a treatment that you set-up and deliver as a clinical trial be an approved therapy. I am hopeful for the future of Sickle cell disease. #research#clinicaltrials#ICHT#ScD
A gene therapy medicine that uses the gene-editing tool CRISPR has been authorised by medical regulators - a UK first. The treatment, Casgevy, is aimed at curing sickle cell disease and β-thalassemia. Read about genome editing and gene therapy in our blog https://t.co/yG1nbwLZue
A gene therapy medicine that uses the gene-editing tool CRISPR has been authorised by medical regulators - a UK first. The treatment, Casgevy, is aimed at curing sickle cell disease and β-thalassemia. Read about genome editing and gene therapy in our blog https://t.co/yG1nbwLZue
@shereenabhani @BOPACommittee@CPCongress This is a pleasant news, I'm pleased to be a part of a comnitted EDI committee and motivated to do more to ensure inclusive practices.
I'm looking forward to being involved in research as a member of the public and not delivering the research. #PPIE#scd#PERICLES https://t.co/Cv4lUCWAg2
With @APTUK1 and @NIHRresearch we’ve just launched the first e-learning module in a series for pharmacists and pharmacy technicians to develop their skills and knowledge in research. Interested? Find out more: https://t.co/SHriBtTsua #Research@davidwebb_1
It was humbling to present some results from the BOPA EDI survey alongside @pascaledettwill4 and had insightful panel discussion on how to make EDI everyone's business! #BOPA2022#EDI